News stories about GTX (NASDAQ:GTXI) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GTX earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.8535695215981 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Brokerages Expect GTx Incorporated (GTXI) to Announce -$0.43 Earnings Per Share (americanbankingnews.com)
- Active-Investors: Blog Exposure – GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI (finanznachrichten.de)
- The Medical Report: Saint Francis promotes new COO; GTx study aims to fix leaks (bizjournals.com)
- GTx completes patient enrollment in a Phase 2 clinical trial of enobosarm in SUI (seekingalpha.com)
- GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence (finance.yahoo.com)
A number of equities analysts recently issued reports on GTXI shares. Zacks Investment Research cut shares of GTX from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. BidaskClub upgraded shares of GTX from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 26th. ValuEngine upgraded shares of GTX from a “sell” rating to a “hold” rating in a research report on Wednesday, February 7th. Stifel Nicolaus boosted their target price on shares of GTX from $16.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, March 5th. Finally, Robert W. Baird reissued a “buy” rating and set a $20.00 target price on shares of GTX in a report on Tuesday, March 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $37.50.
GTX (NASDAQ:GTXI) last posted its earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.05. analysts expect that GTX will post -1.78 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-gtx-gtxi-stock-price.html.
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.